Compare Nomura Holdings Inc (NMR) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nomura Holdings Inc vs Summit Therapeutics Inc — how do they compare? Nomura Holdings Inc trades at $9.48 (market cap $27.55B), while Summit Therapeutics Inc trades at $17.39 (market cap $13.71B). The key difference: Nomura Holdings Inc is far larger — about 2× Summit Therapeutics Inc's market cap, and Nomura Holdings Inc pays a 3.4% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nomura Holdings Inc for 55 Days and Summit Therapeutics Inc for 16 Days on average.
| NMR | SMMT | |
|---|---|---|
Market Cap | $27.55B | $13.71B |
Volume | 782,470 | 6,173,057 |
Sector | Financials | Health |
52-Week High | $10.86 | $26.38 |
52-Week Low | $6.73 | $12.43 |
Typical Hold Time | 55 Days | 16 Days |
Enterprise Value | $38.54T | $13.04B |
Dividend Yield | 3.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nomura Holdings (NMR) trades at $9.53, down 2.56% today amid bearish technical signals. The stock shows mixed fundamentals with strong revenue growth to $1.66T in 2025 and net income margin of 20.4%, but recent earnings misses and negative operating cash flow raise concerns. Valuation appears reasonable with P/E of 11.33 and P/B of 1.15. Analyst sentiment is cautious with 67% hold ratings despite recent Zacks strong buy recommendations.
The outlook remains balanced - attractive valuation and revenue growth potential are offset by cash flow challenges and technical weakness. Key risks include Japan's fiscal policy impacts on bond markets and sustained negative operating cash flow. Investors should weigh the discounted valuation against execution risks in the current macroeconomic environment.
Summit Therapeutics (SMMT) trades at $17.95, up 3.7% with strong technical momentum and bullish analyst sentiment. The stock shows negative profitability metrics but benefits from AstraZeneca's $2 billion strategic investment and clinical collaborations. Recent news highlights positive clinical trial results for ivonescimab, driving investor optimism despite current financial losses.
The outlook remains speculative with significant upside potential based on analyst consensus targets averaging $29.33, though high valuation multiples and negative cash flows present substantial risk. Success of clinical trials and partnership execution will determine long-term value creation for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
